论文部分内容阅读
目的评价国产多西他赛(多帕菲)联合顺铂(DDP)方案(简称DP方案)在治疗老年人晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)中的近期疗效、不良反应的多因素分析。方法对病理证实的78例晚期NSCLC患者,采用DP方案化疗,多帕菲30mg/m2。第1、8d给药,DDP 20mg/m2第1～4d给药,21d为1周期。至少化疗2周期后复查评价疗效。结果本组研究总有效率35.90%,其中Ⅲ期总有效率41.03%,Ⅳ期有效率20.00%。不良反应Ⅲ、Ⅳ度粒细胞减少发生率20.51%.Ⅲ、Ⅳ度血小板减少发生率5.13%,恶心、呕吐的Ⅲ、Ⅳ度发生率为17.95%。结论多帕菲联合DDP方案治疗老年性非小细胞肺癌疗效高且不良反应低,是治疗老年性NSCLC较好的方案,值得进一步推广。
Objective To evaluate the short-term efficacy of the domestic docetaxel (DDP) combined with cisplatin (DP) regimen in the treatment of advanced non-small cell lung cancer (NSCLC). The adverse reactions Multivariate analysis. Methods 78 patients with advanced NSCLC confirmed by pathology were treated with DP regimen and docetaxel 30 mg / m2. The first 1,8d administration, DDP 20mg / m2 on the first ~ 4d administration, 21d for a cycle. After at least 2 cycles of chemotherapy to review the evaluation of efficacy. Results The total effective rate of this study was 35.90%, of which the total effective rate was 41.03% in stage Ⅲ, and the effective rate in stage Ⅳ was 20.00%. Adverse reactions Ⅲ, Ⅳ degree of neutropenia incidence rate of 20.51% .Ⅲ, Ⅳ degree of thrombocytopenia 5.13%, nausea, vomiting Ⅲ, Ⅳ degree was 17.95%. Conclusion Dopamicin combined with DDP regimen for the treatment of senile non-small cell lung cancer with high efficacy and low adverse reactions, is a good solution for the treatment of senile NSCLC, worthy of further promotion.